Therapeutic options for reducing sleep impairment in allergic rhinitis, rhinosinusitis, and nasal polyposis

Current Medical Research and Opinion

Volumn 23, Issue 9, 2007, Pages 2135-2146

  Storms, William ^a   Yawn, Barbara ^b   Fromer, Leonard ^c  

^a William Storms Allergy Clinic   (United States)

^b OLMSTED MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Congestion; Nasal obstruction; Nasal polyposis; Rhinitis; Rhinosinusitis; Sleep

Indexed keywords

AMOXICILLIN; ANTIHISTAMINIC AGENT; AZELASTINE; BECLOMETASONE; BECLOMETASONE DIPROPIONATE; BROMPHENIRAMINE; BUDESONIDE; CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; CYTOKINE; DECONGESTIVE AGENT; DESLORATADINE; DIPHENHYDRAMINE; FEXOFENADINE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; HISTAMINE; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVOCETIRIZINE; LORATADINE; MOMETASONE FUROATE; PHENYLEPHRINE; PHENYLPROPANOLAMINE; PLACEBO; PSEUDOEPHEDRINE; TRIAMCINOLONE ACETONIDE;

ALLERGIC RHINITIS; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DROWSINESS; DRUG MEGADOSE; HEALTH SURVEY; HUMAN; MONOTHERAPY; NOSE CONGESTION; NOSE POLYP; PREVALENCE; QUALITY OF LIFE; REVIEW; RHINOSINUSITIS; SINUS CONGESTION; SLEEP APNEA SYNDROME; SLEEP DISORDER; TACHYCARDIA; URINE RETENTION; ADULT; ARTICLE; CHILD; EUROPE; PERENNIAL RHINITIS; SINUSITIS; UNITED STATES;

ADULT; CHILD; EUROPE; HUMANS; NASAL POLYPS; PREVALENCE; RHINITIS, ALLERGIC, PERENNIAL; SINUSITIS; SLEEP DISORDERS; UNITED STATES;

EID: 36049005921     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X219607     Document Type: Review

References (129)

1. Young T, Finn L, Kim H. Nasal obstruction as a risk factor for sleep-disordered breathing. J Allergy Clin Immunol 1997;99:S757-62
2. Stradling JR, Crosby JH. Predictors and prevalence of obstructive sleep apnoea and snoring in 1001 middle aged men. Thorax 1991;46:85-90
3. Olsen KD, Kern EB. Nasal influences on snoring and obstructive sleep apnea. Mayo Clin Proc 1990;65:1095-105
4. Kenny TJ, Duncavage J, Bracikowski J, et al. Prospective analysis of sinus symptoms and correlation with paranasal computed tomography scan. Otolaryngol Head Neck Surg 2001;125:40-3
5. Radenne F, Lamblin C, Vandezande LM, et al. Quality of life in nasal polyposis. J Allergy Clin Immunol 1999;104:79-84
6. Bousquet J, van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. Allergy 2002;57:841-55
7. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998;81:478-518
8. Bauchau V, Durham SR. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 2004;24:758-64
9. Anand VK. Epidemiology and economic impact of rhinosinusitis. Ann Otol Rhinol Laryngol Suppl 2004;193:3-5
10. Bachert C, Hörmann K, Mösges R, et al. An update on the diagnosis and treatment of sinusitis and nasal polyposis. Allergy 2003;58:176-91
11. Benninger MS, Ferguson BJ, Hadley JA. Adult chronic rhinosinusitis: definitions, diagnosis, epidemiology, and pathophysiology. Otolaryngol Head Neck Surg 2003;129:S1-32
12. Klossek JM, Neukirch F, Pribil C, et al. Prevalence of nasal polyposis in France: a cross-sectional, case-control study. Allergy 2005;60:233-7
13. Johansson L, Akerlund A, Holmberg K, et al. Prevalence of nasal polyps in adults: the Skovde population-based study. Ann Otol Rhinol Laryngol 2003;112:625-9
14. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 1999;28:717-22
15. D'Alonzo GE. Scope and impact of allergic rhinitis. J Am Osteopath Assoc 2002;102(Suppl 2):S2-6
16. Shedden A. Impact of nasal congestion on quality of life and work productivity in allergic rhinitis. Findings from a large online survey. Treat Respir Med 2005;4:438-46
17. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994;93:413-23
18. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991;21:77-83
19. Forbes Consulting Group. Understanding the dynamics surrounding allergy suffering and treatment: US and global results. September 2005
20. Reinberg A, Gervais P, Levi F, et al. Circadian and circannual rhythms of allergic rhinitis: an epidemiologic study involving chronobiologic methods. J Allergy Clin Immunol 1988;81:51-62
21. Smolensky MH, Reinberg A, Labrecque G. Twenty-four hour pattern in symptom intensity of viral and allergic rhinitis: treatment implications. J Allergy Clin Immunol 1995;95:1084-96
22. Fokkens W, Lund V, Bachert C, et al. EAACI position paper on rhinosinusitis and nasal polyps executive summary. Allergy 2005;60:583-601
23. Bhattacharyya N. The economic burden and symptom manifestations of chronic rhinosinusitis. Am J Rhinol 2003;17:27-32
24. Meltzer EO, Hamilos DL, Hadley JA, et al. Rhinosinusitis: establishing definitions for clinical research and patient care. J Allergy Clin Immunol 2004;114:5155-212
25. Settipane RA. Complications of allergic rhinitis. Allergy Asthma Proc 1999;20:209-13
26. Lack G. Pediatric allergic rhinitis and comorbid disorders. J Allergy Clin Immunol 2001;108:S9-15
27. Mansfield LE, Diaz G, Posey CR, et al. Sleep disordered breathing and daytime quality of life in children with allergic rhinitis during treatment with intranasal budesonide. Ann Allergy Asthma Immunol 2004;92:240-4
28. Ferguson BJ. Influences of allergic rhinitis on sleep. Otolaryngol Head Neck Surg 2004;130:617-9
29. Lavie P, Gertner R, Zomer J, et al. Breathing disorders in sleep associated with 'microarousals' in patients with allergic rhinitis. Acta Otolaryngol 1981;92:529-33
30. McNicholas WT, Tarlo S, Cole P, et al. Obstructive apneas during sleep in patients with seasonal allergic rhinitis. Am Rev Respir Dis 1982;126:625-8
31. Staevska MT, Mandajieva MA, Dimitrov VD. Rhinitis and sleep apnea. Curr Allergy Asthma Rep 2004;4:193-9
32. McColley SA, Carroll JL, Curtis S, et al. High prevalence of allergic sensitization in children with habitual snoring and obstructive sleep apnea. Chest 1997;111:170-3
33. Chester AC. Symptoms of rhinosinusitis in patients with unexplained chronic fatigue or bodily pain: a pilot study. Arch Intern Med 2003;163:1832-6
34. Serrano E, Neukirch F, Pribil C, et al. Nasal polyposis in France: impact on sleep and quality of life. J Laryngol Otol 2005;119:543-9
35. Flemons WW, Tsai W. Quality of life consequences of sleep-disordered breathing. J Allergy Clin Immunol 1997;99:S750-6
36. Marshall PS, O'Hara C, Steinberg P. Effects of seasonal allergic rhinitis on selected cognitive abilities. Ann Allergy Asthma Immunol 2000;84:403-10
37. Wilken JA, Berkowitz R, Kane R. Decrements in vigilance and cognitive functioning associated with ragweed-induced allergic rhinitis. Ann Allergy Asthma Immunol 2002;89:372-80
38. Kessler RC, Almeida DM, Berglund P, et al. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol 2001;87:289-95
39. Spaeth J, Klimek L, Mosges R. Sedation in allergic rhinitis is caused by the condition and not by antihistamine treatment. Allergy 1996;51:893-906
40. Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001;108:S45-53
41. Vuurman EF, van Veggel LM, Uiterwijk MM, et al. Seasonal allergic rhinitis and antihistamine effects on children's learning. Ann Allergy 1993;71:121-6
42. Simons FE. Learning impairment and allergic rhinitis. Allergy Asthma Proc 1996;17:185-9
43. Urschitz MS, Guenther A, Eggebrecht E, et al. Snoring, intermittent hypoxia and academic performance in primary school children. Am J Respir Crit Care Med 2003;168:464-8
44. Urschitz MS, Eitner S, Guenther A, et al. Habitual snoring, intermittent hypoxia, and impaired behavior in primary school children. Pediatrics 2004;114:1041-8
45. Kremer B, den Hartog HM, Jolles J. Relationship between allergic rhinitis, disturbed cognitive functions and psychological well-being. Clin Exp Allergy 2002;32:1310-5
46. Juniper EF, Rohrbaugh T, Meltzer EO. A questionnaire to measure quality of life in adults with nocturnal rhinoconjunctivitis. J Allergy Clin Immunol 2003;111:484-90
47. Kakumanu S, Glass C, Craig T. Poor sleep and daytime somnolence in allergic rhinitis: significance of nasal congestion. Am J Respir Med 2002;1:195-200
48. Storms WW. Pharmacologic approaches to daytime and nighttime symptoms of allergic rhinitis. J Allergy Clin Immunol 2004;114:S146-53
49. Rundcrantz H. Postural variations of nasal patency. Acta Otolaryngol 1969;68:435-43
50. Corey JP, Houser SM, Ng BA. Nasal congestion: a review of its etiology, evaluation, and treatment. Ear Nose Throat J 2000;79:690-3, 696, 698
51. Young T, Finn L, Palta M. Chronic nasal congestion at night is a risk factor for snoring in a population-based cohort study. Arch Intern Med 2001;161:1514-9
52. Quraishi SA, Davies MJ, Craig TJ. Inflammatory responses in allergic rhinitis: traditional approaches and novel treatment strategies. J Am Osteopath Assoc 2004;104(Suppl 5):S7-15
53. Craig TJ, Teets S, Lehman EB, et al. Nasal congestion secondary to allergic rhinitis as a cause of sleep disturbance and daytime fatigue and the response to topical nasal corticosteroids. J Allergy Clin Immunol 1998;101:633-7
54. Craig TJ, McCann JL, Gurevich F, et al. The correlation between allergic rhinitis and sleep disturbance. J Allergy Clin Immunol 2004;114:S139-45
55. Chen W, Kushida CA. Nasal obstruction in sleep-disordered breathing. Otolaryngol Clin North Am 2003;36:437-60
56. Tashiro M, Mochizuki H, Iwabuchi K, et al. Roles of histamine in regulation of arousal and cognition: functional neuroimaging of histamine H1 receptors in human brain. Life Sci 2002;72:409-14
57. Krouse HJ, Davis JE, Krouse JH. Immune mediators in allergic rhinitis and sleep. Otolaryngol Head Neck Surg 2002;126:607-13
58. Mullington JM, Hinze-Selch D, Pollmacher T. Mediators of inflammation and their interaction with sleep: relevance for chronic fatigue syndrome and related conditions. Ann N Y Acad Sci 2001;933:201-10
59. Gelfand EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 2004;114:S135-8
60. Blaiss M. Quality of life in allergic rhinitis. Ann Allergy Asthma Immunol 1999;83:449-54
61. American Academy of Allergy, Asthma and Immunology 2000. The Allergy Report. Available from http://www.aaaai.org/ar/default.htm [Last accessed 12 December 2006]
62. Berger WE, Lumry WR, Meltzer EO, et al. Efficacy of desloratadine, 5 mg, compared with fexofenadine, 180 mg, in patients with symptomatic seasonal allergic rhinitis. Allergy Asthma Proc 2006;27:214-23
63. Meltzer EO, Scheinmann P, Rosado Pinto JE, et al. Safety and efficacy of oral fexofenadine in children with seasonal allergic rhinitis - a pooled analysis of three studies. Pediatr Allergy Immunol 2004;15:253-60
64. Potter PC, on behalf of the Study Group. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. Allergy 2003;58:893-9
65. Horak F, Stübner P, Zieglmeyer R, et al. Comparison of the effects of desloratadine 5-mg daily and placebo on nasal airflow and seasonal allergic rhinitis symptoms induced by grass pollen exposure. Allergy 2003;58:481-5
66. Lieberman P, Kaliner MA, Wheeler WJ. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr Med Res Opin 2005;21:611-8
67. Corren J, Storms W, Bernstein J, et al; Azelastine Cetirizine Trial No. 1 (ACT 1) Study Group. Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis. Clin Ther 2005;27:543-53
68. Lieberman P, Kaliner MA, Wheeler WJ. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis. Curr Med Res Opin 2005;21:611-8
69. Davies RJ, Bagnall AC, McCabe RN, et al. Antihistamines: topical vs oral administration. Clin Exp Allergy 1996;26(Suppl 3):11-7
70. Berlin JM, Golden SJ, Teets S, et al. Efficacy of a steroid nasal spray compared with an antihistamine nasal spray in the treatment of perennial allergic rhinitis. J Am Osteopath Assoc 2000;100(Suppl 7):S8-13
71. Ratner P, Sacks H. Randomized, double-blind trial of azelastine nasal spray plus fluticasone nasal spray compared to either agent alone in patients with allergy to Texas mountain cedar. Presented at: 2006 ACAAI Annual Scientific Meeting; November 9-15, 2006; Philadelphia, Pa
72. Astelin [package insert]. Somerset, NJ: Medpointe Pharmaceuticals; 2003
73. Bousquet J, van Cauwenberge P, Khaltaev N; ARIA Workshop Group, WHO. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(Suppl):S147-336
74. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317:1624-9
75. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. Allergy 2000;55:116-34
76. Nayak AS, Settipane GA, Pedinoff A, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol 2002;89:271-8
77. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol 2005;116:1289-95
78. Bloom M, Staudinger H. Effect of mometasone furoate nasal spray (MFNS) on nasal polyposis. J Allergy Clin Immunol 2004;113(Suppl):S282
79. Gawchik S, Goldstein S, Prenner B, et al. Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003;90:416-21
80. Mandl M, Nolop K, Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 1997;79:370-8
81. Berger WE, Nayak AS, Staudinger HW. Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother 2005;39:1984-9
82. Stjärne P, Blomgren K, Cayé-Thomasen P, et al. The efficacy and safety of once-daily mometasone furoate nasal spray in nasal polyposis: a randomized, double-blind, placebo-controlled study. Acta Otolaryngol 2006;126:606-12
83. Ortolani C, Foresi A, Di Lorenzo G, et al; FLNCO2 Italian Study Group. A double-blind, placebo-controlled comparison of treatment with fluticasone propionate and levocabastine in patients with seasonal allergic rhinitis. Allergy 1999;54:1173-80
84. Parikh A, Scadding GK, Darby Y, et al. Topical corticosteroids in chronic rhinosinusitis: a randomized, double-blind, placebo-controlled trial using fluticasone propionate aqueous nasal spray. Rhinology 2001;39:75-9
85. Holmberg K, Juliusson S, Balder B, et al. Fluticasone propionate aqueous nasal spray in the treatment of nasal polyposis. Ann Allergy Asthma Immunol 1997;78:270-6
86. Penttila M, Poulsen P, Hollingworth K, et al. Dose-related efficacy and tolerability of fluticasone propionate nasal drops 400 microg once daily and twice daily in the treatment of bilateral nasal polyposis: a placebo-controlled randomized study in adult patients. Clin Exp Allergy 2000;30:94-102
87. Ratner PH, Howland WC 3rd, Jacobs RL, et al. Relief of sinus pain and pressure with fluticasone propionate aqueous nasal spray: a placebo-controlled trial in patients with allergic rhinitis. Allergy Asthma Proc 2002;23:259-63
88. Gurevich F, Glass C, Davies M, et al. The effect of intranasal steroid budesonide on sleep disturbance and daytime somnolence in patients with perennial allergic rhinitis. Allergy Asthma Proc 2005;26:268-74
89. Hughes K, Glass C, Ripchinski M, et al. Efficacy of the topical nasal steroid budesonide on improving sleep and daytime somnolence in patients with perennial allergic rhinitis. Allergy 2003;58:380-5
90. Berger WE, Kaiser H, Gawchik SM, et al. Triamcinolone acetonide aqueous nasal spray and fluticasone propionate are equally effective for relief of nasal symptoms in patients with seasonal allergic rhinitis. Otolaryngol Head Neck Surg 2003;129:16-23
91. Ozturk F, Turktas I, Asal K, et al. Effect of intranasal triamcinolone acetonide on bronchial hyperresponsiveness in children with seasonal allergic rhinitis and comparison of perceptional nasal obstruction with acoustic rhinometric assessment. Int J Pediatr Otorhinolaryngol 2004;68:1007-15
92. Lund VJ, Black JH, Szabo LZ, et al. Efficacy and tolerability of budesonide aqueous nasal spray in chronic rhinosinusitis patients. Rhinology 2004;42:57-62
93. Tos M, Svendstrup F, Arndal H, et al. Efficacy of aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps. Am J Rhinol 1998;12:183-9
94. DeMain JG, Goetz DW. Pediatric adenoidal hypertrophy with nasal airway obstruction: reduction with nasal beclomethasone. Pediatrics 1995;95:355-64
95. Craig TJ, Mende C, Hughes K, et al. The effect of topical nasal fluticasone on objective sleep testing and the symptoms of rhinitis, sleep and daytime somnolence in perennial allergic rhinitis. Allergy Asthma Proc 2003;24:53-8
96. Bender BG, Milgrom H. Comparison of the effects of fluticasone propionate aqueous nasal spray and loratadine on daytime alertness and performances in children with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004;92:344-9
97. Kiely JL, Nolan P, McNicholas WT. Intranasal corticosteroid therapy for obstructive sleep apnoea in patients with co-existing rhinitis. Thorax 2004;59:50-5
98. Milgrom H, Biondi R, Georgitis JW, et al. Comparison of ipratropium bromide 0.03% with beclomethasone dipropionate in the treatment of perennial rhinitis in children. Ann Allergy Asthma Immunol 1999;83:105-11
99. Potter PC, Van Niekerk CH, Schoeman HS. Effects of triamcinolone on quality of life in patients with persistent allergic rhinitis. Ann Allergy Asthma Immunol 2003;91:368-74
100. Mintz M, Garcia J, Diener P, et al. Triamcinolone acetonide aqueous nasal spray improves nocturnal rhinitis-related quality of life in patients in a primary care setting: the Quality of Sleep in Allergic Rhinitis study. Ann Allergy Asthma Immunol 2004;92:255-61
101. Bachert C, Meltzer EO, Staudinger H, et al. Effect of mometasone furoate on the health-related quality of life of patients with acute rhinosinusitis. Presented at: World Allergy Congress 2005; June 26-July 1, 2005; Munich, Germany [Abstract 112]
102. Cutler DL, Banfield C, Melton B, et al. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006;19:46-53
103. Kamenov S, Kamenov B, Moskovljevic J, et al. Intranasal budesonide treatment of rhino-sinusitis improves quality of life in school children. Presented at: World Allergy Congress 2005; June 26-July 1, 2005; Munich, Germany [Abstract 713]
104. Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg 2003;129:739-50
105. Allen DB. Systemic effects of intranasal steroids: an endocrinologist's perspective. J Allergy Clin Immunol 2000;106:S179-90
106. Boner AL. Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children. J Allergy Clin Immunol 2001;108(1 Suppl):S32-9
107. Wolthers OD, Pedersen S. Knemometric assessment of systemic activity of once daily intranasal dry-powder budesonide in children. Allergy 1994;49:96-9
108. Cutler DL, Banfield C, Affrime MB. Safety of mometasone furoate nasal spray in children with allergic rhinitis as young as 2 years of age: a randomized controlled trial. Pediatr Asthma Allergy Immunol 2006;19:146-53
109. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000;105:E22
110. Möller C, Ahlström H, Henricson KA, et al. Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003;33:816-22
111. Wolthers OD, Pedersen S. Short-term growth in children with allergic rhinitis treated with oral antihistamine, depot and intranasal glucocorticosteroids. Acta Paediatr 1993;82:635-40
112. Skoner DP, Gentile D, Angelini B, et al. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:56-62
113. Agertoft L, Pedersen S. Short-term lower leg growth rate in children with rhinitis treated with intranasal mometasone furoate and budesonide. J Allergy Clin Immunol 1999;104:948-52
114. Minshall E, Ghaffar O, Cameron L, et al. Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998;118:648-54
115. Baroody FM, Cheng CC, Moylan B, et al. Absence of nasal mucosal atrophy with fluticasone aqueous nasal spray. Arch Otolaryngol Head Neck Surg 2001;127:193-9
116. Lindqvist N, Balle VH, Karma P, et al. Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis. A 12-month multicentre study. Allergy 1986;41:179-86
117. Klossek JM, Laliberte F, Laliberte MF, et al. Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long-term treatment of perennial allergic rhinitis. Rhinology 2001;39:17-22
118. Klimek L, Bachert C, Hormann K. Steroid sprays in non-infectious rhinitis and sinusitis. Proper and regular spraying does not damage the nasal mucosa. MMW Fortschr Med 2002;144:41-3
119. Meltzer EO. Intranasal steroids: managing allergic rhinitis and tailoring treatment to patient preference. Allergy Asthma Proc 2005;26:445-51
120. Dupclay L Jr, Doyle J. Assessment of intranasal corticosteroid use in allergic rhinitis: benefits, costs, and patient preferences. Am J Man Care 2002;8(Suppl):S335-40
121. Hendeles L, Hatton RC. Oral phenylephrine: an ineffective replacement for pseudoephedrine? J Allergy Clin Immunol 2006;118:279-80
122. Goldbart AD, Goldman JL, Veling MC, et al. Leukotriene modifier therapy for mild sleep-disordered breathing in children. Am J Respir Crit Care Med 2005;172:364-70
123. Ohta N, Sakurai S, Yoshitake H, et al. Study of the effects of anti-leukotriene receptor antagonists on chronic allergic rhinitis - using QOL as an index. Presented at: World Allergy Congress 2005; June 26-July 1, 2005; Munich, Germany [Abstract 704]
124. Moinuddin R, deTineo M, Maleckar B, et al. Comparison of the combinations of fexofenadine-pseudoephedrine and loratadine-montelukast in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2004;92:73-9
125. Wilson AM, O'Byrne PM, Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med 2004;116:338-44
126. Di Lorenzo G, Pacor ML, Pellitteri ME, et al. Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in monotherapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis. Clin Exp Allergy 2004;34:259-67
127. Alobid I, Benitez P, Bernal-Sprekelsen M, et al. Nasal polyposis and its impact on quality of life: comparison between the effects of medical and surgical treatments. Allergy 2005;60:452-8
128. Tuncer U, Soylu L, Aydogan B, et al. The effectiveness of steroid treatment in nasal polyposis. Auris Nasus Larynx 2003;30:263-8
129. Ragab SM, Lund VJ, Scadding G. Evaluation of the medical and surgical treatment of chronic rhinosinusitis: a prospective, randomised, controlled trial. Laryngoscope 2004;114:923-30